234 related articles for article (PubMed ID: 23013428)
21. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
[TBL] [Abstract][Full Text] [Related]
22. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
McBride A; Lathon SC; Boehmer L; Augustin KM; Butler SK; Westervelt P
Pharmacotherapy; 2013 Mar; 33(3):295-303. PubMed ID: 23456733
[TBL] [Abstract][Full Text] [Related]
23. Rasburicase: future directions in tumor lysis management.
Hochberg J; Cairo MS
Expert Opin Biol Ther; 2008 Oct; 8(10):1595-604. PubMed ID: 18774926
[TBL] [Abstract][Full Text] [Related]
24. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
Martens KL; Khalighi PR; Li S; White AA; Silgard E; Frieze D; Estey E; Garcia DA; Hingorani S; Li A
Leuk Res; 2020 Feb; 89():106298. PubMed ID: 31945598
[TBL] [Abstract][Full Text] [Related]
25. A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.
Eng S; Lee CS; Ahn S; Sharma A
J Oncol Pharm Pract; 2020 Mar; 26(2):338-344. PubMed ID: 31088218
[TBL] [Abstract][Full Text] [Related]
26. Assessment of rasburicase utilization for tumor lysis syndrome management in pediatric and adult patients in the inpatient and outpatient settings.
Abousaud MI; Rush MC; Rockey M
J Oncol Pharm Pract; 2021 Jul; 27(5):1165-1171. PubMed ID: 32727320
[TBL] [Abstract][Full Text] [Related]
27. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Cammalleri L; Malaguarnera M
Int J Med Sci; 2007 Mar; 4(2):83-93. PubMed ID: 17396159
[TBL] [Abstract][Full Text] [Related]
28. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
[TBL] [Abstract][Full Text] [Related]
29. Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
Savva DA; Herrera N; Rohatgi R
Pediatr Blood Cancer; 2018 Oct; 65(10):e27236. PubMed ID: 29905398
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome.
Patel S; Le A; Gascon S
Am J Health Syst Pharm; 2012 Jun; 69(12):1015-6. PubMed ID: 22644973
[No Abstract] [Full Text] [Related]
31. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
Goldman SC; Holcenberg JS; Finklestein JZ; Hutchinson R; Kreissman S; Johnson FL; Tou C; Harvey E; Morris E; Cairo MS
Blood; 2001 May; 97(10):2998-3003. PubMed ID: 11342423
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
Digumarti R; Sinha S; Nirni SS; Patil SG; Pedapenki RM
Indian J Cancer; 2014; 51(2):180-3. PubMed ID: 25104205
[TBL] [Abstract][Full Text] [Related]
33. Rasburicase-Induced Methemoglobinemia in a Patient with Aggressive Non-Hodgkin's Lymphoma.
Alessa MA; Craig AK; Cunningham JM
Am J Case Rep; 2015 Sep; 16():590-3. PubMed ID: 26334783
[TBL] [Abstract][Full Text] [Related]
34. The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome.
Boutin A; Blackman A; O'Sullivan DM; Forcello N
J Oncol Pharm Pract; 2019 Apr; 25(3):577-583. PubMed ID: 29320954
[TBL] [Abstract][Full Text] [Related]
35. Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification.
Khalighi PR; Martens KL; White AA; Li S; Silgard E; Frieze D; Garcia DA; Li A
J Oncol Pharm Pract; 2020 Apr; 26(3):529-535. PubMed ID: 31167612
[TBL] [Abstract][Full Text] [Related]
36. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study.
De Angelis S; Noce A; Di Renzo L; Cianci R; Naticchia A; Giarrizzo GF; Giordano F; Tozzo C; Splendiani G; De Lorenzo A
Eur Rev Med Pharmacol Sci; 2007; 11(3):179-84. PubMed ID: 17970234
[TBL] [Abstract][Full Text] [Related]
37. Rasburicase dose optimization for tumor lysis syndrome management in a network of community oncology practices.
Gilmore S; Carroll M; Koselke E; Hough S
J Oncol Pharm Pract; 2024 Jul; 30(5):867-872. PubMed ID: 37563922
[TBL] [Abstract][Full Text] [Related]
38. Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
Shaikh SA; Marini BL; Hough SM; Perissinotti AJ
J Oncol Pharm Pract; 2018 Apr; 24(3):176-184. PubMed ID: 28077046
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
Pei Y; Li Y; Liang Y; Xu L; Huang X; Li Y; Tang W; Jiang X
Int J Clin Pharm; 2020 Dec; 42(6):1440-1446. PubMed ID: 32974856
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
Gupta G; Seth T; Garg V; Juneja R; Mahapatra M; Datta SK; Upadhyay AD; Saxena R
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e99-e104. PubMed ID: 33039358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
